Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)

10Citations
Citations of this article
N/AReaders
Mendeley users who have this article in their library.

Abstract

In the original article, there was an error. The IRB Number of our article, “IRB No: 202100961B0”, was typed mistakenly as “IRB No: 20210096B0”. A correction has been made to the last sentence of the Materials and Methods, Patients and the Ethics Statement”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Cite

CITATION STYLE

APA

Kuo, Y. H., Lu, S. N., Chen, Y. Y., Kee, K. M., Yen, Y. H., Hung, C. H., … Wang, J. H. (2021, December 14). Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767). Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2021.823960

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free